BeiGene Ltd. (BGNE)

136.29
6.99 4.88
NASDAQ : Health Technology
Prev Close 143.28
Open 142.53
Day Low/High 135.26 / 149.62
52 Wk Low/High 105.19 / 220.10
Volume 527.91K
Avg Volume 614.50K
Exchange NASDAQ
Shares Outstanding 59.31M
Market Cap 8.39B
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BeiGene And SpringWorks Therapeutics Enter Into Global Clinical Collaboration To Evaluate Targeted Combination Therapy In Advanced Solid Tumors

BeiGene And SpringWorks Therapeutics Enter Into Global Clinical Collaboration To Evaluate Targeted Combination Therapy In Advanced Solid Tumors

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a...

Celgene Says Juno, Impact Deals Won't Be Its Last

Celgene Says Juno, Impact Deals Won't Be Its Last

The biopharmaceutical giant's top executive says the company will continue to aggressively invest in R&D and deploy capital to acquire or license assets.

TheStreet Quant Rating: D (Sell)